We evaluated the effect of estrogens on "free" and total calcitriol levels and on the calcitriol response to a hypocalcemic challenge in 12 postmenopausal women, age 55-74 yr. Endogenous calcitriol production was induced by intravenous Na-EDTA before and after conjugated estrogens, 1.25 mg/d for 30 d. Free calcitriol was determined by centrifugal ultrafiltration and by the molar ratio of calcitriol to vitamin D-binding protein (DBP). Estrogen increased fasting total calcitriol from 38.5±3.8 to 62.3±7.0 pg/ml (P < 0.05). This was accompanied by a rise in free calcitriol from 104.5±11.4 to 158.7±16.4 fg/ml (P < 0.05). Vitamin D-binding protein increased from 348±16 to 428±12 jig/ml (P < 0.001), and the ratio of calcitriol/DBP increased from 1.50±0.14 to 1.94±0.18 (P < 0.005), confirming the rise in free calcitriol. Increases in free calcitriol and in calcitriol/DBP ratios were significantly correlated, r = 0.72. Hypocalcemia led to a rapid increase in circulating immunoreactive parathyroid hormone, and to a rise in calcitriol at 24 h. The hypocalcemia-induced rise in total and free calcitriol was similar before and after estrogen, whether expressed as increments or as percent changes. We conclude that estrogen increases circulating levels of biologically active free calcitriol in postmenopausal women, but that a 30-d period of estrogen administration does not apparently improve the renal la-hydroxylase response to a PTH challenge.
Introduction
Elevated plasma levels of the active vitamin D metabolite, 1,25(OH)2 vitamin D (calcitriol), have been commonly observed during physiologic states of increased circulating estrogen (1) (2) (3) (4) (5) and during administration of either oral contraceptive medications (4) or postmenopausal estrogens (1) . However, since estrogen also increases the production of vitamin D binding protein (6, 7) , an increase in total calcitriol is not necessarily accompanied by a rise in the biologically effective free level. Gallagher et al. (1) showed that the efficiency of intestinal calcium absorption in menopausal women improved in parallel with an estrogen-induced rise in serum calcitriol, suggesting that biologically active calcitriol had indeed increased. However, Crilly et al. (8) reported in an abstract that estrogen treatment of osteoporotic women did not affect either free calcitriol or calcium absorption. We have assessed the effects of estrogen on circulating total and free calcitriol levels Subjects. Healthy postmenopausal women were recruited from a registry maintained by the Aging Study Unit, Veterans Administration Medical Center Palo Alto, of normal elderly men and women in the Palo Alto community. Subjects were invited to participate in this study if they had no chronic or acute illness, were not taking estrogen replacement, thiazide diuretics, glucocorticosteroids, lithium carbonate, anticonvulsant medication, or any other drug known to affect mineral metabolism, and if they had no contraindication to receiving estrogen therapy. Subjects underwent an initial screening procedure which included health history questionnaire, physical examination, electrocardiogram, nutritional assessment, and multiphasic laboratory panel.
12 women, age 55-75 yr, passed the screening criteria and were enrolled into the protocol. One woman had undergone hysterectomy without oophorectomy. One woman received one-grain equivalent of thyroid hormone replacement on a chronic basis. Two women continued their habitual daily supplement of calcium, 500 and 1,000 mg, throughout the study. One woman had taken estrogen (0.3 mg conjugated estrogen/d) for 30 d, > 2 mo before the study. The were placed into a 70 X 100 mm test tube, and dried under nitrogen. 0.45 ml serum which had been diluted 1:10 in phosphate-buffered saline was added; aliquots were removed, and each was placed in the inner tube of an ultrafiltration vial (12) and centrifuged at 2,000 g for 90 min at 370C. After centrifugation, 30 41 of the contents ofthe inner tube (representing serum) and the contents of the outer vial (ultrafiltrate) were analyzed for 3H and 14C by liquid scintillation spectroscopy (model LS3801; Beckman Instruments, Fullerton, CA). The percentage of free calcitriol was calculated from the following equation: % free = 3HU/'4CU . 3H,/'4CS X 100, where u = ultrafiltrate and s = serum. The concentration of free calcitriol was calculated by multiplying the measured total calcitriol by the percent free.
Serum calcium was determined by automatic titration against EGTA (Calcette, model 4008; Precision Systems, Inc., Natick, MA). Vitamin D binding protein was measured by Dr. Roger Bouillon by methods reported previously (13).
Data management. The database was maintained on a personal computer and analyzed with the Crunch statistical software package (Crunch Software, Oakland, CA). Analyses included paired t tests and repeated measures analysis of variance. Probability tests were two tailed. Data are reported as means±SEM.
Results
Characteristics of the study group are shown in Table I 3 .68±0.14 to 3.33±0.1 1 mg/dl, respectively (P < 0.05) (Table  II) . Estrogen treatment did not alter fasting iPTH. Total fasting Fig. 1 ). At baseline, the free calcitriol concentration was 104.5± 11 fg/ml, representing 0.279±0.01% of total (Table IV ). This calcitriol level is significantly lower (P < 0.05) than corresponding values obtained for a group of 10 healthy women, age 25-40 yr, in whom percent free calcitriol was 0.220±0.01%, and the free calcitriol concentration was 145±12 fg/ml. On estrogen, free calcitriol increased significantly to 158.7±16.4 fg/ml (P < 0.05) ( Table IV, Fig. 1 ), a value that was indistinguishable from that of the young controls.
To validate the rise in basal free calcitriol levels on estrogen, vitamin D-binding protein (DBP) was measured on fasting serum before and after estrogen treatment (Table V) . Initial DBP was 348±16 gg/ml, increasing significantly to 428±12 gg/ml on estrogen (P < 0.001). The index of free calcitriol, defined as the molar ratio of total calcitriol to DBP, increased significantly on estrogen, from 1.50±0.14 to 1.94±0.18 (P < 0.005). The rise in fasting free calcitriol by centrifugal ultrafiltration correlated significantly with the rise in the calcitriol/DBP ratio, r = 0.72, P < 0.05.
Effect ofestrogen on the response to EDTA-hypocalcemia.
EDTA infusion lead to a rapid and progressive fall in the serum calcium concentration, with a concomitant rise in iPTH (Fig. 2) . The hypocalcemic nadirs with EDTA were simi- hypocalcemia was significantly lower after estrogen than during the first study (P = 0.05) (Fig. 2 , Table II ). Serum calcitriol levels began to rise by 4 h of the EDTA infusion, and were highest at 24 h (Fig. 2) . Before estrogen therapy, the hypocalcemic challenge led to significant rises in total calcitriol concentration in 10 of 12 women (Table III) (Fig. 1) . The mean baseline value, 38.5±3.8 pg/ml, rose to a peak of 51.5±4.1 pg/ml, representing a 40% increase of 13.0±3.4 pg/ml. After estrogen, hypocalcemia increased calcitriol in 10 women, with peak levels of 75.2±6.8 pg/ml that were significantly higher than those achieved before estrogen. However, the increase from basal, expressed either as absolute rise or fold increase, did not differ significantly from preestrogen values (Fig. 1) .
The percent free calcitriol did not change during or after the EDTA infusion. Before estrogen hypocalcemia increased the concentration of free calcitriol in 10 women (Table IV, Fig.   1 Hammond et al. (12), we found free calcitriol levels in our postmenopausal subjects to be significantly lower than those of younger women. After estrogen, these levels increased to the normal young range. The concentrations of free calcitriol that we report are reasonably close to, but slightly lower than those described by Bikle et al. (2), a difference that may reflect our use of a 1:10 dilution of serum in the assay in order to enhance the precision of the method. To confirm the ultrafiltration results, we examined the effect of estrogen on DBP and on the free calcitriol index of Bouillon et al. (4) . DBP concentrations before treatment were similar to those reported for normal adult women. On estrogen, DBP rose to levels almost as high as those observed in women taking combination estrogen/progestin contraceptives (4). The index of free calcitriol, or calcitriol/DBP ratio, was initially lower than that reported for adult women, but increased on estrogen to levels observed in young women taking (19) have both shown that phosphorus deprivation increases calcitriol levels in healthy men. In this study, serum phosphorus levels decreased significantly after estrogen. However, there was no correlation between the reduction in serum phosphorus and the rise in calcitriol, so this issue remains unresolved. It is possible that the relationship between phosphorus and calcitriol production is more complex than can be determined from single fasting specimens, and more frequent sampling would be necessary for significant correlations to emerge.
Finally, one must consider the possibility that estrogen directly stimulates calcitriol production by modulating la-hydroxylase activity. Evidence for and against such a direct effect in avian species has been presented (20) (21) (22) (23) , but there is presently no compelling evidence for a direct effect of estrogen on the hydroxylase system in mammals.
Circulating levels of calcitriol decrease with age in normal humans (24, 25) . In elderly women, the rise in calcitriol concentration that follows administration of PTH is blunted (26, 27) , suggesting that impaired activation of the rate limiting enzyme in calcitriol synthesis, la-hydroxylase, contributes to the decreased plasma sterol levels. A possible role for estrogen deprivation in this impairment has not been addressed. Because estrogen replacement increases the plasma calcitriol concentration in postmenopausal women (1), it is possible that hydroxylase unresponsiveness may partly reflect the hormonal milieu rather than age per se. If this were true, the calcitriol response to PTH might improve after estrogen replacement. Within the constraints of the experimental protocol, our results provide no support for this hypothesis. Whereas the hypocalcemic challenge increased total and free calcitriol levels in 10 of 12 women with the initial study, only eight subjects showed a rise in free calcitriol after estrogen. Moreover, the group changes in total and free calcitriol after EDTA were the same after as before estrogen, regardless of whether the data are expressed as absolute or relative changes.
Nonetheless, it would be premature to conclude that estrogen does not modify the sensitivity of 1 a-hydroxylase to its primary regulators. The stimulus to calcitriol formation in this study was not PTH alone, but the combination of PTH and hypocalcemia. The level of hypocalcemia achieved during the two EDTA studies was the same. However, because basal calcium levels were slightly lower on estrogen, the decrease from basal calcemia was not as great. The induced rise in iPTH was also slightly less during the second study. Thus, neither stimulus was strictly comparable during the two tests. Furthermore, even if the tests had been identical in every detail, one could not draw firm conclusions about enzyme sensitivity from what is essentially a single-point dose response. Comprehensive assessment of renal sensitivity to PTH will require the elaboration of complete response curves to graded doses of hormone. From the perspective of maintaining bone mass, it is widely accepted that the best opportunity for estrogen replacement therapy is within a few years of menopause, during the period ofaccelerated bone loss. However, age-related bone loss continues into later decades, and is thought to be sustained by a complex interaction of marginal vitamin D sufficiency, intestinal calcium malabsorption, and compensatory hypersecretion of PTH (1, 9, 10, 28 ). An estrogen-related increase in biologically effective, free calcitriol levels in women who were on average > 15 yr beyond menopause supports the idea that some of the factors that underlie age-related bone loss may improve with the judicious replacement of estrogen, even in later years.
